Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Glaukos revenue
Glaukos's revenue is $383.5 million.
What is Glaukos's revenue?
- Glaukos's revenue growth from 2014 to 2024 is 741.21%.
- Glaukos has 437 employees, and the revenue per employee ratio is $877,530.
- Glaukos's peak quarterly revenue was $105.5M in 2024(q4).
- Glaukos peak revenue was $383.5M in 2024.
- Glaukos annual revenue for 2023 was 314.7M, 11.26% growth from 2022.
- Glaukos annual revenue for 2024 was 383.5M, 21.85% growth from 2023.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
Glaukos historical revenue
Glaukos's peak revenue was $383.5M in 2024. The peak quarterly revenue was $105.5M in 2024(q4).
Glaukos's revenue increased from $45.6m in 2014 to $383.5M currently. That's a 741.21% change in annual revenue.
Glaukos annual revenue
Glaukos annual revenue over time
| Fiscal year / year | Glaukos revenue |
|---|---|
| 2014 | $45.6M |
| 2015 | $71.7M |
| 2016 | $114.4M |
| 2017 | $159.3M |
| 2018 | $181.3M |
| 2019 | $237.0M |
| 2020 | $225.0M |
| 2021 | $294.0M |
| 2022 | $282.9M |
| 2023 | $314.7M |
| 2024 | $383.5M |
How accurately did Glaukos' revenue projections match actual performance?
Glaukos annual growth
Glaukos saw the greatest revenue growth in 2016, when revenue increased by 59.55%.
Glaukos had the lowest revenue growth in 2020, when revenue changed by -5.07%.
Glaukos annual growth rate over time
| Year | Glaukos growth |
|---|---|
| 2015 | 57%↑ |
| 2016 | 60%↑ |
| 2017 | 39%↑ |
| 2018 | 14%↑ |
| 2019 | 31%↑ |
| 2020 | -5%↓ |
| 2021 | 31%↑ |
| 2022 | -4%↓ |
| 2023 | 11%↑ |
| 2024 | 22%↑ |
Glaukos quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Glaukos quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2015 | - | $17.8M | $19.0M | $20.3M |
| 2016 | $23.1M | $28.6M | $29.6M | $33.2M |
| 2017 | $35.9M | $41.3M | $40.4M | $41.7M |
| 2018 | $40.1M | $43.2M | $43.9M | $54.1M |
| 2019 | $54.0M | $58.6M | $58.5M | $65.8M |
| 2020 | $55.3M | $31.6M | $64.8M | $73.2M |
| 2021 | $68.0M | $78.1M | $74.7M | $73.2M |
| 2022 | $67.7M | $72.7M | $71.3M | $71.2M |
| 2023 | $73.9M | $80.4M | $78.0M | $82.4M |
| 2024 | $85.6M | $95.7M | $96.7M | $105.5M |
Glaukos jobs nearby
Do you work at Glaukos?
Did Glaukos meet its revenue projections?
Glaukos financial information
| CEO | Thomas William Burns |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 437 |
| Date Founded | 1998 |
| Headquarters | San Clemente, California |
| Number of Locations | 8 |
| Revenue | $383.5M |
| Net Income | -$99,195,000 |
| Gross Proft | $289.5M (2024) |
| PE Ratio | -7.93 |
| Tax Rate | -0.0% |
| Market Capitalization | $1.2B |
| Total Assets | $1,002,383,000 |
| Ticker | GKOS |
Glaukos jobs you might like
Glaukos financing
Glaukos received early financing of $10.0M on 2002-09-01.
| Series | Round size | Date |
|---|---|---|
| Series A | $10M | 09/2002 |
| Series D | $35M | 08/2008 |
| Debt Financing | $6M | 09/2010 |
| Series E | $29.5M | 02/2011 |
| Debt Financing | $4.5M | 08/2012 |
| Debt Financing | $6M | 10/2012 |
| Series F | $30M | 02/2013 |
Glaukos investors
| Investors | Security type |
|---|---|
| Versant Ventures | Series A |
| Frazier Healthcare Partners | Series A |
| Domain Associates | Series A |
| Versant Ventures | Series D |
| InterWest Partners | Series D |
| Frazier Healthcare Partners | Series D |
| Fjord Ventures | Series D |
| OrbiMed Advisors | Series D |
| Domain Associates | Series D |
| Montreux Equity Partners | Series D |
| Versant Ventures | Series E |
| Frazier Healthcare Partners | Series E |
| Fjord Ventures | Series E |
| OrbiMed Advisors | Series E |
| Meritech Capital Partners | Series E |
| Domain Associates | Series E |
| Montreux Equity Partners | Series E |
| Versant Ventures | Series F |
| InterWest Partners | Series F |
| Frazier Healthcare Partners | Series F |
| OrbiMed Advisors | Series F |
| Meritech Capital Partners | Series F |
| Domain Associates | Series F |
| Montreux Equity Partners | Series F |
Glaukos competitors
Glaukos's top competitor, BioMarin, earned an annual revenue of $2.9B.
Glaukos's smallest competitor is Medigus with revenue of $531.0K last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| FzioMed | - | $5.0M | 20 | - |
| STAAR® Surgical Co | - | $313.9M | 806 | - |
| Silk Road Medical | - | $177.1M | 281 | - |
| Dextera Surgical | - | $3.4M | 50 | - |
| iScience Interventional | - | $1.7M | 30 | - |
| Sight Sciences | - | $79.9M | 147 | - |
| Medigus | - | $531,000 | 20 | - |
| Enable Injections | - | $24.8M | 300 | - |
| Genentech | - | $166.9M | 13,638 | - |
| BioMarin | - | $2.9B | 2,581 | - |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Glaukos highest paying jobs
Zippia gives an in-depth look into the details of Glaukos, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Glaukos. The employee data is based on information from people who have self-reported their past or current employments at Glaukos. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Glaukos. The data presented on this page does not represent the view of Glaukos and its employees or that of Zippia.
Glaukos may also be known as or be related to GLAUKOS CORP, GLAUKOS Corp, Glaukos, Glaukos Corp. and Glaukos Corporation.